… the event, ProQR will highlight its proprietary Axiomer™ ADAR-mediated RNA editing platform, along with updates on its … join the analyst Q&A session with the Management Team. Additionally, the following speakers will present at the …
… Results Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and … areas Strength of intellectual property estate and leading IP position supported with successful defense of opposition against a key Axiomer patent protecting ADAR-mediated RNA editing Well-capitalized with €139 M, in …
… of the EONs, Neutral linkage modifications in the ADAR-binding region (ABR) have a positive impact on editing … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are …
… Editing Oligonucleotides (EONs) recruit endogenous ADAR to make single nucleotide changes to RNA in a highly … Gerard Platenburg, Chief Innovation Officer at ProQR added, “We are the first to show evidence of RNA editing … an endogenously expressed RNA editing system called ADAR, which it can direct to change an Adenosine (A) to an …
… will provide an overview of ProQR’s proprietary ADAR-mediated Axiomer RNA editing technology platform, … for therapeutic development of editing oligonucleotides. Additionally, the presentation will detail AX-0810, the …
… to execute on our strategy.” Recent Progress Continue to advance AX-0810 for patients suffering from cholestatic … cardiovascular risk. ProQR plans to present and publish additional preclinical data from these two pipeline programs … Chardan Genetic Medicines Conference panel discussion on “ ADAR RNA Editing: Unlocking New Therapeutic Opportunities ”. …